Logo image
Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes
Journal article   Open access   Peer reviewed

Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes

Amanda L Horton, Yinglei Lai, Dwight J Rouse, Catherine Y Spong, Kenneth J Leveno, Michael W Varner, Brian M Mercer, Jay D Iams, Ronald J Wapner, Yoram Sorokin, …
American journal of perinatology, v 32(4), pp 387-392
Mar 2015
PMID: 25241107
url
https://europepmc.org/articles/pmc4369158View
Accepted (AM) Open

Abstract

Adult Cerebral Palsy - prevention & control Delivery, Obstetric Female Fetal Membranes, Premature Rupture - drug therapy Gestational Age Humans Infant, Newborn Infant, Premature Infant, Premature, Diseases - prevention & control Magnesium Sulfate - therapeutic use Neuroprotective Agents - therapeutic use Obstetric Labor, Premature - prevention & control Pregnancy Tocolytic Agents - therapeutic use Treatment Outcome Young Adult
This study aims to evaluate whether magnesium sulfate administration for neuroprotection prolongs latency in women with preterm premature rupture of membranes (PPROM) between 24 and 31(6/7) weeks' gestation. This is a secondary analysis of a randomized controlled trial of magnesium sulfate for prevention of cerebral palsy. Gravid women with a singleton pregnancy between 24 and 31(6/7) weeks' gestation with PPROM without evidence of labor were randomized to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour up to 12 hours, or placebo. Maternal outcomes for this analysis were delivery in less than 48 hours and in less than 7 days from randomization. Neonatal outcomes included a composite of respiratory distress syndrome, interventricular hemorrhage grades 3 or 4, periventricular leukomalacia, sepsis, necrotizing enterocolitis, retinopathy of prematurity, or death. A total of 1,259 women were included. The rate of delivery < 48 hours was not different in the magnesium sulfate and the placebo groups (22.2 and 20.7%, p = 0.51). Delivery < 7 days was similar between groups (55.4 and 51.4%, p = 0.16). Median latency was also similar between groups (median [interquartile range], 6.0 days [range, 2.4-13.8 days] and 6.6 days [range, 2.4-15.1 days], p = 0.29). Composite neonatal outcomes did not differ between groups. Magnesium sulfate administration given for neuroprotection in women with a singleton gestation with PPROM and without labor before 32 weeks does not impact latency.

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Obstetrics & Gynecology
Pediatrics
Logo image